Alector reports inducement grants as permitted by the nasdaq listing rules

South san francisco, calif., jan. 03, 2022 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation committee of alector's board of directors granted sara kenkare-mitra, ph.d., the company's newly-hired president and head of research and development an inducement equity grant on january 3, 2022, consisting of inducement stock options to purchase an aggregate of 300,000 shares of the company's common stock, inducement restricted stock units, or rsus, covering an aggregate of 59,000 shares of the company's common stock, and inducement performance stock units, or psus, covering an aggregate of 59,000 shares of the company's common stock. these inducement stock options, inducement rsus, and inducement psus are subject to the terms of alector's 2022 inducement equity incentive plan and related forms of agreements and were granted as inducements material to new employees entering into employment with alector in accordance with nasdaq listing rule 5635(c)(4).
ALEC Ratings Summary
ALEC Quant Ranking